VTX-27

• Description :

  VTX-27 is a selective protein kinase C θ (PKC θ) inhibitor, with Kis of 0.08 nM and 16 nM for PKC θ and PKC δ.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  PKC

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; TGF-beta/Smad

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/VTX-27.html

• Purity :

  99.73

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  FC1=C(N=C(N2C[C@@](NCC2)([H])[C@](C)(O)C(C)C)C(Cl)=C1)C3=NNC4=NC=CC=C34

• Molecular Formula :

  C20H24ClFN6O

• Molecular Weight :

  418.90

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Jimenez JM, et al. Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases. J Med Chem. 2013 Mar 14;56 (5) :1799-810.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PKCα; PKCδ; PKCθ

• CAS Number :

  [1321924-70-2]